Key facts
- NewVision’s last known valuation is $16.2M (Jun 2025).
- It has raised $11.8M; the latest was Later Stage VC ($6.2M) in Jun 2025.
- Notable investors include LRM, Andoverpia Invest, Buysse & Partners, Fadek-Invest, N3X Investments — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for NewVision
- ·The full record, as it builds
Funding rounds
No funding rounds for NewVision are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NewVision
Developer of an ophthalmology platform designed to help people to get vision. The company's platform focuses on ophthalmology and eye care to take care of non-medical matters, enabling patients to receive good quality and safe eye care, transparent communication, and accessibility for everyone.
- Sector
- Healthcare
- HQ
- Edegem, Belgium
- Founded
- 2015
- Employees
- 13
- Website
- newvision.be/
- Ownership
- Privately Held (backing)
NewVision doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NewVision shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NewVision in its N-PORT filings yet. We sweep new filings monthly.